Fig. 6. Centi-C10 pharmacokinetics in a preclinical mouse model. Centi-C10 antibody was administered to scid FcRn-/- hFcRn (32) Tg mice via three different routes and the pharmacokinetics were assessed as shown in (a) via ELISA. Pharmacokinetic parameters were determined by fitting the Centi-C10 serum concentration profiles using a two-phase decay for the (b) IV bolus or a single compartment model for the (c) subcutaneous bolus. (d) Two compartment model incorporating the subcutaneous depot that was applied to fit the pharmacokinetic profile of the (e) SC gel group, using first order rate constants determined from the IV and SC bolus data. Data points shown as mean ± SD (n = 3 prior to 24 h, otherwise n = 6; for gel group, n ≥ 4 after day 63); calculated PK values shown as mean ± SE.